Psy Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC
  • (Cancelled)

  • Investors
  • 4

Psy Therapeutics General Information

Description

Developer of novel small molecule therapies designed to treat central nervous system disorders such as pain, Parkinson's disease, and PTSD (Post-traumatic stress disorder). The company offers brain-penetrant, well-tolerated drug candidates based on a chemistry-driven, de-risked approach, enabling patients affected by serious neurological conditions to access more effective and better-tolerated treatments.

Contact Information

Website
www.psythx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 28 Atlantic Avenue
  • Suite 222
  • Boston, MA 02110
  • United States
Primary Industry
Drug Discovery
Corporate Office
  • 28 Atlantic Avenue
  • Suite 222
  • Boston, MA 02110
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Psy Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC Cancelled Pre-Clinical Trials
3. Seed Round 09-Sep-2025 Completed Pre-Clinical Trials
2. Seed Round 23-Dec-2021 $2.4M $6.4M Completed Startup
1. Seed Round 01-Oct-2019 $4M $4M Completed Startup
To view Psy Therapeutics’s complete valuation and funding history, request access »

Psy Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view Psy Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Psy Therapeutics Patents

Psy Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025245367-A1 Inhibiting catechol-o-methyltransferase (comt) Pending 22-May-2024
WO-2025010394-A2 Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of inflammatory conditions Inactive 06-Jul-2023
WO-2025010394-A3 Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of inflammatory conditions Inactive 06-Jul-2023
WO-2025010392-A2 Monoacylglycerol lipase inhibitors and use thereof for the treatment of neurological disorders Inactive 06-Jul-2023
WO-2025010392-A3 Monoacylglycerol lipase inhibitors and use thereof for the treatment of neurological disorders Inactive 06-Jul-2023 A61P25/08
To view Psy Therapeutics’s complete patent history, request access »

Psy Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ayuh Ventures Venture Capital Minority
JLS Fund Venture Capital Minority
Palo Santo Venture Capital Minority
WPSS.bio Venture Capital Minority
To view Psy Therapeutics’s complete investors history, request access »

Psy Therapeutics FAQs

  • When was Psy Therapeutics founded?

    Psy Therapeutics was founded in 2016.

  • Where is Psy Therapeutics headquartered?

    Psy Therapeutics is headquartered in Boston, MA.

  • What industry is Psy Therapeutics in?

    Psy Therapeutics’s primary industry is Drug Discovery.

  • Is Psy Therapeutics a private or public company?

    Psy Therapeutics is a Private company.

  • What is Psy Therapeutics’s current revenue?

    The current revenue for Psy Therapeutics is .

  • How much funding has Psy Therapeutics raised over time?

    Psy Therapeutics has raised $13.2M.

  • Who are Psy Therapeutics’s investors?

    Ayuh Ventures, JLS Fund, Palo Santo, and WPSS.bio have invested in Psy Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process